View
Semantic Search: Obesity Triples Infection Death Risk
Obesity Triples Infection Death Risk
Score 0.833
· Account tjphuhs@gmail.com
· 2/23/2026, 9:04:35 AM
Obesity Triples Infection Death Risk from news@twc.health on 2026-02-23T14:04:35.000Z What you can do to avoid becoming a statistic. This email was sent to you as HTML-only. To view it, please visit: https://arn.soundestlink.com/ce/v/66f59766ed7d70230df9f78b/699918a220810ef02c8537dc ************************** Make sure you keep getting our latest offers and add news@twc.health to your address book. Unsubscribe https://arn.soundestlink.com/contactsPreferences/v2/unsubscribe/?b=6480deeecefd2884c0f
Fwd: When Ozempic stops working (and what 10% of users already know)
Score 0.606
· Account tjphuhs@gmail.com
· 3/17/2026, 2:05:41 PM
Fwd: When Ozempic stops working (and what 10% of users already know) from tjphuhs@gmail.com on 2026-03-17T18:05:41.000Z to lose even 5% of body weight, the minimum threshold considered clinically meaningful. In the SURMOUNT-2 trial for tirzepatide, 17-21% of participants didn't hit that 5% mark. Why? Variants in the GLP-1 receptor gene affect how strongly the drug signals satiety. Gut microbiome composition also influences response. And if your metabolism is already adapted to caloric restrictio
4 Minute Fridays: The four-minute exercise that cuts death risk by 40%, why you should never wear shoes in the home & I track this biomarker every 6 months to avoid heart disease
Score 0.582
· Account tjphuhs@gmail.com
· 5/8/2026, 11:05:45 AM
4 Minute Fridays: The four-minute exercise that cuts death risk by 40%, why you should never wear shoes in the home & I track this biomarker every 6 months to avoid heart disease from dan@highperformancefounder.com on 2026-05-08T15:05:45.000Z Read this on Dango.co ( https://986419df.click.convertkit-mail4.com/xmu93wwloei6hp6wvdwa5h2eenp0efnhdrr0w/reh8hohmzgew49s2/aHR0cHM6Ly93d3cuZGFuZ28uY28vYmxvZy80LW1pbnV0ZS1mcmlkYXlzLW1heS04dGgtMjAyNg== ) Welcome to 4 Minute Fridays, my weekly newsletter, w
4 Minute Fridays: The four-minute exercise that cuts death risk by 40%, why you should never wear shoes in the home & I track this biomarker every 6 months to avoid heart disease
Score 0.580
· Account tjphuhs@gmail.com
· 5/8/2026, 11:05:45 AM
4 Minute Fridays: The four-minute exercise that cuts death risk by 40%, why you should never wear shoes in the home & I track this biomarker every 6 months to avoid heart disease from dan@highperformancefounder.com on 2026-05-08T15:05:45.000Z wearable device-measured vigorous intermittent lifestyle physical activity with mortality. Nat Med. 2022 Dec;28(12):2521-2529. doi: 10.1038/s41591-022-02100-x. Epub 2022 Dec 8. PMID: 36482104; PMCID: PMC9800274. * https://ciriscience.org/ieq-measurement/st
Fwd: Reta vs. Cancer
Score 0.576
· Account tjphuhs@gmail.com
· 2/26/2026, 12:51:09 AM
Fwd: Reta vs. Cancer from tjphuhs@gmail.com on 2026-02-26T05:51:09.000Z at lower doses, these metabolic changes may be meaningful. Non-Cancer-Favoring Terrain Cancer develops within biological terrain. A body with high fasting glucose A body with elevated insulin A body with systemic inflammation A body with immune dysfunction These conditions create fertile ground for pathological growth. Retatrutide appears to influence multiple pathways simultaneously. It improves glucose regulation, flattens
Fwd: When Ozempic stops working (and what 10% of users already know)
Score 0.575
· Account tjphuhs@gmail.com
· 3/17/2026, 2:05:41 PM
Fwd: When Ozempic stops working (and what 10% of users already know) from tjphuhs@gmail.com on 2026-03-17T18:05:41.000Z Rate Problem Retatrutide is Eli Lilly's triple agonist (GIP/GLP-1/glucagon). Early results: up to 24.2% weight loss at 48 weeks per the NEJM Phase 2 trial. But buried in the data: dose-dependent increases in heart rate peaking at 24 weeks. The glucagon receptor component is the likely culprit. At the 12mg dose, heart rate elevations were clinically notable. Users report resting
Do GLP-1s Kill Your Testosterone?
Score 0.575
· Account tjphuhs@gmail.com
· 4/28/2026, 10:43:24 AM
Do GLP-1s Kill Your Testosterone? from derekpruski@substack.com on 2026-04-28T14:43:24.000Z (STEP 1) Tirzepatide: ~21% loss at 72 weeks (SURMOUNT-1) Peptide-R (triple-agonist): ~24% at 48 weeks (phase 2), and 28.7% at 68 weeks in the recent phase 3 TRIUMPH-4 readout. Placebo-adjusted: 26.6%. Once weight loss gets that aggressive, you’re no longer just dropping fat — you’re forcing the body into sustained caloric deficit territory that the HPG axis interprets as famine. And the famine response is
Fwd: Reta vs. Cancer
Score 0.573
· Account tjphuhs@gmail.com
· 2/26/2026, 12:56:32 AM
Fwd: Reta vs. Cancer from tjphuhs@gmail.com on 2026-02-26T05:56:32.000Z improves insulin sensitivity and reduces hyperglycemia. That shift may reduce the availability of fuel and the growth signals that tumors rely on. Even at lower doses, these metabolic changes may be meaningful. Non-Cancer-Favoring Terrain Cancer develops within biological terrain. A body with high fasting glucose A body with elevated insulin A body with systemic inflammation A body with immune dysfunction These conditions cr
Fwd: Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast.
Score 0.570
· Account tjphuhs@gmail.com
· 3/17/2026, 3:31:51 PM
Fwd: Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast. from tjphuhs@gmail.com on 2026-03-17T19:31:51.000Z things: “this compound has been studied for visceral fat” and “this compound burns visceral fat.” Those aren’t the same statement. Not even close. So let’s actually pull this apart. Upgrade to paid What Is Visceral Fat, and Why Does It Matter? Before anything else, it helps to understand what we’re actually talking about. Your body stores fat in two main places. Subcutaneous fat
Reta vs. Cancer
Score 0.569
· Account tjphuhs@gmail.com
· 2/24/2026, 6:06:31 PM
Reta vs. Cancer from huntershealthhacks@mail.beehiiv.com on 2026-02-24T23:06:31.000Z that metabolism and cancer are closely linked. Elevated insulin. Elevated glucose. Chronic inflammation. Visceral adiposity. Impaired immune surveillance. These factors create conditions that favor tumor growth. If a compound improves glucose control, lowers inflammatory tone, enhances insulin sensitivity, and potentially influences immune function, it is reasonable to consider that it could support a less cance
Fwd: Reta vs. Cancer
Score 0.567
· Account tjphuhs@gmail.com
· 2/26/2026, 12:56:32 AM
Fwd: Reta vs. Cancer from tjphuhs@gmail.com on 2026-02-26T05:56:32.000Z a frontline immune checkpoint cancer therapy in reducing tumor growth in this model. Interestingly, this study was not centered on dramatic weight loss or appetite suppression. The dose used did not significantly affect body weight, yet tumor growth decreased meaningfully. Retatrutide’s benefits go far beyond cosmetic fat loss. They are metabolic. They are immunologic. They may even profoundly reshape the body's internal ter
Fwd: Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast.
Score 0.567
· Account tjphuhs@gmail.com
· 3/17/2026, 3:31:51 PM
Fwd: Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast. from tjphuhs@gmail.com on 2026-03-17T19:31:51.000Z doesn’t exist for Ipamorelin in humans. But the mechanism is there, the cortisol problem is largely absent, and the GH response is real. MK-677 (Ibutamoren) MK-677 is the outlier of the group. It’s taken orally — no injection required — and has a half-life of around 24 hours, meaning it keeps GH and IGF-1 elevated throughout the day rather than producing discrete pulses. It actu
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast.
Score 0.567
· Account tjphuhs@gmail.com
· 3/17/2026, 2:53:19 PM
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast. from derekpruski@substack.com on 2026-03-17T18:53:19.000Z a population with naturally declining GH — over six months. Fat mass decreased. Lean mass increased. Visceral fat wasn’t the specific endpoint, so we don’t have precise imaging data. But the directional result is exactly what you’d expect given the mechanism. The honest limitation here is that 10 minutes may simply not be long enough to drive consistent, meaningful visceral fa
Why are young women getting colon cancer at record rates?
Score 0.566
· Account tjphuhs@gmail.com
· 3/29/2026, 5:03:14 PM
Why are young women getting colon cancer at record rates? from hello@lineageprovisions.com on 2026-03-29T21:03:14.000Z [Remembering Vol. 64](https://lineageprovisions.com/a/collections/products?= subscriptions=3Dfalse) [Tip of the week](https://pubmed.ncbi.nlm.nih.gov/41231486/) [Dr. Paul's latest](https://www.youtube.com/watch?v=3DuxmCrmz6dTU) [Shocking but true](https://lineageprovisions.com/products/100-grass-fed-be= ef-tallow) [Shocking but true](https://www.scientificamerican.com/article/ul
What If You Could Lose Weight Effortlessly?
Score 0.565
· Account tjphuhs@gmail.com
· 5/13/2026, 11:36:40 PM
What If You Could Lose Weight Effortlessly? from laglujmxoicybl.40323419322994@yicdk9.lyb7e2.qi0u3s.us on 2026-05-14T03:36:40.000Z Top Stories of the Day: Wed, 13 May 2026 23:36:40 -0400 207282808238797353 ----- ceofddbjzhffmljhtpernhquowftwejivlniaqrwqnhqoikiatftsfqjeazjxcwaujgmczonrimwaywdcavlsnrtlbxdcsbjmuwiauedzvfpemdbckwgbfbakrbyjmglcpyopfxlygnzuqxjzzkawfsoslkphxpjhounpwhsjewzmaorblte If you believe this has been sent to you in error, please safely unsubscribe
Fwd: Semaglutide and Alcohol: A New Study in The Lancet is Worthy of Attention
Score 0.564
· Account tjphuhs@gmail.com
· 5/1/2026, 9:18:21 AM
Fwd: Semaglutide and Alcohol: A New Study in The Lancet is Worthy of Attention from tjphuhs@gmail.com on 2026-05-01T13:18:21.000Z condition that accounts for 5% of deaths worldwide every year. Those medications help some people, and that certainly matters. It matters in the same way that phentermine and orlistat mattered to obesity. A useful way to think about how well a treatment works is something called the number needed to treat, which captures how many people have to take the drug for one p
Fwd: Semaglutide and Alcohol: A New Study in The Lancet is Worthy of Attention
Score 0.564
· Account oc.tjphuhs@gmail.com
· 5/1/2026, 9:18:21 AM
Fwd: Semaglutide and Alcohol: A New Study in The Lancet is Worthy of Attention from tjphuhs@gmail.com on 2026-05-01T13:18:21.000Z condition that accounts for 5% of deaths worldwide every year. Those medications help some people, and that certainly matters. It matters in the same way that phentermine and orlistat mattered to obesity. A useful way to think about how well a treatment works is something called the number needed to treat, which captures how many people have to take the drug for one p
Fwd: Reta vs. Cancer
Score 0.564
· Account tjphuhs@gmail.com
· 2/26/2026, 12:51:09 AM
Fwd: Reta vs. Cancer from tjphuhs@gmail.com on 2026-02-26T05:51:09.000Z or appetite suppression. The dose used did not significantly affect body weight, yet tumor growth decreased meaningfully. Retatrutide’s benefits go far beyond cosmetic fat loss. They are metabolic. They are immunologic. They may even profoundly reshape the body's internal terrain. FYI, BioLongevity Labs is running a storewide sale where everything is 30% off. Use code HUNTERW to get an additional 15% off. The Study The resea
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast.
Score 0.563
· Account tjphuhs@gmail.com
· 3/17/2026, 2:53:19 PM
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast. from derekpruski@substack.com on 2026-03-17T18:53:19.000Z and it’s notable for being the most cortisol-sparing of the GHRPs. That distinction matters for this conversation. Cortisol — your primary stress hormone — is one of the main drivers of visceral fat accumulation. Some GHRPs, particularly GHRP-2 and GHRP-6 at higher doses, raise cortisol meaningfully, which can actively work against visceral fat reduction. Ipamorelin largely av
Fwd: Nobody Lost 7 Pounds of Fat in Their First Week on a GLP-1. Let's Talk About Why.
Score 0.562
· Account oc.tjphuhs@gmail.com
· 3/16/2026, 10:27:30 AM
Fwd: Nobody Lost 7 Pounds of Fat in Their First Week on a GLP-1. Let's Talk About Why. from tjphuhs@gmail.com on 2026-03-16T14:27:30.000Z TJ Begin forwarded message: From: Derek from Peptide Price <derekpruski@substack.com> Date: March 16, 2026 at 10:25:49 AM EDT To: tjphuhs@gmail.com Subject: Nobody Lost 7 Pounds of Fat in Their First Week on a GLP-1. Let's Talk About Why. Reply-To: Derek from Peptide Price <reply+35so0v&4iwoe6&&82edb6be5b009f85c0744544f02d4a5269faf369ed1e663207a198ec47c9f0d9@m
Fwd: Nobody Lost 7 Pounds of Fat in Their First Week on a GLP-1. Let's Talk About Why.
Score 0.562
· Account tjphuhs@gmail.com
· 3/16/2026, 10:27:30 AM
Fwd: Nobody Lost 7 Pounds of Fat in Their First Week on a GLP-1. Let's Talk About Why. from tjphuhs@gmail.com on 2026-03-16T14:27:30.000Z TJ Begin forwarded message: From: Derek from Peptide Price <derekpruski@substack.com> Date: March 16, 2026 at 10:25:49 AM EDT To: tjphuhs@gmail.com Subject: Nobody Lost 7 Pounds of Fat in Their First Week on a GLP-1. Let's Talk About Why. Reply-To: Derek from Peptide Price <reply+35so0v&4iwoe6&&82edb6be5b009f85c0744544f02d4a5269faf369ed1e663207a198ec47c9f0d9@m
4 Minute Fridays: The four-minute exercise that cuts death risk by 40%, why you should never wear shoes in the home & I track this biomarker every 6 months to avoid heart disease
Score 0.560
· Account tjphuhs@gmail.com
· 5/8/2026, 11:05:45 AM
4 Minute Fridays: The four-minute exercise that cuts death risk by 40%, why you should never wear shoes in the home & I track this biomarker every 6 months to avoid heart disease from dan@highperformancefounder.com on 2026-05-08T15:05:45.000Z founding members. We're opening the waitlist in the next couple of weeks. Keep an eye on your inbox. Here's what caught my attention this week... ***************************** Here is your 4 Minute Friday: ***************************** ---------------------
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast.
Score 0.560
· Account tjphuhs@gmail.com
· 3/17/2026, 2:53:19 PM
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast. from derekpruski@substack.com on 2026-03-17T18:53:19.000Z View this post on the web at https://derekpruski.substack.com/p/does-tesamorelin-have-a-monopoly There’s a claim that gets repeated constantly in the peptide research space: “Tesamorelin is the only peptide proven to burn visceral fat.” And if you’ve spent any time researching GH secretagogues, you’ve probably accepted this as settled fact and moved on. I did for a while too.
Fwd: Reta vs. Cancer
Score 0.560
· Account tjphuhs@gmail.com
· 2/26/2026, 12:51:09 AM
Fwd: Reta vs. Cancer from tjphuhs@gmail.com on 2026-02-26T05:51:09.000Z model without causing weight loss, that suggests its metabolic influence runs deeper than body composition changes alone. That opens the door to considering this molecule within a broader longevity framework. Final Thoughts We are still early in the research. Human data will be essential before drawing firm conclusions. Even so, the data's direction is compelling. Improving metabolic signaling alone influenced tumor biology
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast.
Score 0.559
· Account tjphuhs@gmail.com
· 3/17/2026, 2:53:19 PM
Does Tesamorelin Have a Monopoly on Visceral Fat? Not So Fast. from derekpruski@substack.com on 2026-03-17T18:53:19.000Z makes called Growth Hormone-Releasing Hormone, or GHRH. Your hypothalamus — a small structure deep in your brain — produces GHRH naturally to tell your pituitary gland to release growth hormone. Tesamorelin mimics that signal. It was developed and studied specifically in HIV/AIDS patients who developed a condition called lipodystrophy. When antiretroviral drugs became widely u